Abstract
Current guidelines on germline mutation testing for patients suspected of having Lynch syndrome are not entirely clear in patients with tumors demonstrating isolated loss of PMS2 immunohistochemical expression. We analyzed the clinical and pathologic features of patients with tumors demonstrating isolated loss of PMS2 expression in an attempt to (1) determine the frequency of germline MLH1 and PMS2 mutations and (2) correlate mismatch-repair protein immunohistochemistry and tumor histology with germline mutation results. A total of 3213 consecutive colorectal carcinomas and 215 consecutive endometrial carcinomas were prospectively analyzed for DNA mismatch-repair protein expression by immunohistochemistry. In total, 32 tumors from 31 patients demonstrated isolated loss of PMS2 immunohistochemical expression, including 16 colorectal carcinomas and 16 endometrial carcinomas. Microsatellite instability (MSI) polymerase chain reaction was performed in 29 tumors from 28 patients with the following results: 28 tumors demonstrated high-level MSI, and 1 tumor demonstrated low-level MSI. Twenty of 31 (65%) patients in the study group had tumors demonstrating histopathology associated with high-level MSI. Seventeen patients underwent germline mutation analysis with the following results: 24% with MLH1 mutations, 35% with PMS2 mutations, 12% with PMS2 variants of undetermined significance, and 29% with no mutations in either MLH1 or PMS2. Three of the 4 patients with MLH1 germline mutations had a mutation that results in decreased stability and quantity of the MLH1 protein that compromises the MLH1-PMS2 protein complex, helping to explain the presence of immunogenic but functionally inactive MLH1 protein within the tumor. The high frequency of MLH1 germline mutations identified in our study has important implications for testing strategies in patients suspected of having Lynch syndrome and indicates that patients with tumors demonstrating isolated loss of PMS2 expression without a germline PMS2 mutation must have MLH1 mutation analysis performed.
摘要
目前检测疑似林奇综合征患者胚系突变的指南对于存在PMS2免疫组化表达单独缺失的肿瘤患者并不完全清楚。我们分析存在PMS2表达单独缺失的肿瘤患者临床及病理特征,试图确定(1)MLH1和PMS2突变的频率,(2)错配修复蛋白免疫组化表达和肿瘤组织学与胚系突变结果的联系。连续对总共3213例结直肠癌和215例子宫内膜癌进行 DNA错配修复蛋白免疫组化表达的前瞻性分析。
来自31名患者的32例肿瘤证实存在PMS2免疫组化的单独缺失,其中包括16例结直肠癌和16例子宫内膜癌。对来自28名患者的29例肿瘤进行微卫星不稳定(MSI)聚合酶链反应检测,结果显示:28例肿瘤存在高水平MSI,1例肿瘤存在低水平MSI。该研究小组中 的20/31(65%)例患者组织病理学与高水平MSI有关。17例患者进行胚系突变分析结果如下:24%存在MLH1突变,35%存在PMS2突变,12%存在不确定意义的PMS2变异,29%无MLH1或PMS2突变。4例MLH1胚系突变患者中的3例存在一种突变导致MLH1蛋白稳定性和数量下降,使得MLH1-PMS2蛋白复合物减少,从而帮助解释了肿瘤中MLH1蛋白存在免疫原性但功能不活跃的原因。
本研究中高频率MLH1胚系突变的结果,对于怀疑存在林奇综合征患者的检测具有重要意义 ,并表明无PMS2胚系突变但存在PMS2表达单独缺失的肿瘤患者必须进行MLH1突变分析检测。
共0条评论